Linksbridge

Linksbridge expands the capacity of NGOs, IGOs, and nonprofits to improve human lives.

More than a consultancy, more than a research and advisory firm, and more than a creative agency – Linksbridge combines excellence in each of these professional services with a passion for effecting change

08/06/2026

With a new vaccine development partner in its roster, a second candidate now in Phase 1 trials and a recently launched public resource linking African research institutions with vaccine developers, the CEPI response to the Bundibugyo ebolavirus outbreak is moving quickly on multiple fronts.

More on these developments and other pharma news important to global health in this week's highlights.

Ebola: CEPI expands vaccine lineup, Moderna shot enters clinical Hilleman Laboratories has joined the roster of CEPI-supported companies developing vaccines against Bundibugyo ebolavirus (BDBV). CEPI announced last week that it will provide the Singapore-based joint venture between Merck and Wellcom

07/30/2026

Innovation without access is injustice.

At the 26th International AIDS Conference this week, breakthrough HIV prevention tools like lenacapavir and Merck's investigational PrEP pill are colliding with a $2 billion donor funding retreat and licensing deals that leave out some LMICs—a stark reminder that scientific progress means little without equitable access.

More on the conference, progress for RSV and malaria vaccines, trial data for a child-friendly alternative for treating trichuriasis, and more in this week's highlights.

AIDS 2026: Innovation outpacing access Access was top of mind as the 2026 International AIDS Conference kicked off this week in Rio de Janeiro. FUNDING CUTS THREATEN PROGRESS The conference got underway amid competing realities: the world is on the cusp of transforming HIV prevention while also faci

07/23/2026

Tools for combating TB are advancing on every front: prevention, treatment, and screening.

SII is set to manufacture the M72/AS01E vaccine candidate if Phase 3 trials succeed, an investigational therapy for drug-resistant TB has shown promise in a first-in-human trial, and new Unitaid/CHAI agreements aim to cut the cost of AI-powered TB screening software in LMICs by up to 65%.

Get the full breakdown on these developments—plus malaria treatment R&D, the first Bundibugyo ebolavirus vaccine trial, and more global health pharma news—in this week's highlights.

TB news: Vaccine manufacturing tie-up, new drug data, AI screening deal Serum Institute of India will throw its manufacturing might behind the M72/AS01E tuberculosis vaccine and plans to invest $100 million of its own resources to support the potential future supply of the candidate. That’s accord...

07/02/2026

Local manufacturing of vaccines, drugs, and diagnostics continues to gain ground across Africa and South Asia: Kenya just unveiled a five-year production roadmap, and in Sri Lanka, Sunshine Healthcare and India's Zydus Lifesciences recently broke ground on a $20 million pharmaceutical plant.

More on these developments in this week's issue of Linksbridge Pharma News.

Local manufacturing advances in Africa, South Asia Kenya has launched a five-year roadmap to bolster domestic production of vaccines, drugs and diagnostics. As reported by HealthCare Middle East & Africa on Sunday, the three-pillar strategy seeks to accelerate regulatory and policy reforms, expand l

06/11/2026

Linksbridge Pharma News continues to track the latest industry news related to the Bundibugyo virus outbreak.

In this week’s highlights, Public Health Vaccines scored funding from BARDA and CEPI to advance Bundibugyo vaccine development, Regeneron’s monoclonal antibody maftivimab joined the list of potential treatments to prioritize for clinical trials, TIB Molbiol shared that it’s offering a Bundibugyo diagnostic to frontline health systems, and more.

Ebola: New vaccine funding and collaborations Global health actors are taking additional steps to fight the Ebola outbreak caused by the Bundibugyo virus in DRC and Uganda, building on measures we covered last week. rVSV jabs win new funds: Massachusetts-based Public Health Vaccines (PHV) said Tuesd

06/04/2026

Less than four years after it was selected as the hub of the WHO-led mRNA tech transfer program, Afrigen's mRNA facility in Cape Town has notched GMP certification. But key challenges remain, including ensuring governments procure locally made products even if they're initially more expensive.

This week's highlights cover African vaccine manufacturing, the Ebola outbreak response, shorter regimens for drug-susceptible TB, and more.

Afrigen reaches GMP milestone Afrigen’s mRNA facility in Cape Town has become the first facility on the continent to notch GMP certification, Health Policy Watch reported last week. The development comes less than four years after the company was selected as the hub of the WHO-led mRNA tech transf...

05/28/2026

Eli Lilly made a power move back into vaccines and infectious diseases this week, scooping up three vaccine developers focused on chlamydia, Epstein-Barr virus, staph and other pathogens. More on this update and other pharma news important to global health in this week's highlights.

Lilly makes $4B play for infectious disease vaccines Eli Lilly is back in the vaccines game. The company announced Tuesday that it will shell out close to $4 billion to acquire a trio of companies developing vaccines for viral pathogens linked to long-term neurological and oncological risk, and for

05/21/2026

Serum Institute of India says it needs less than a month to manufacture doses of an experimental vaccine ready for testing against the rare species of Ebola spreading in DRC and Uganda.

More on efforts to combat Bundibugyo virus and other pharma news important to global health in this week's highlights.

Ebola outbreak: race for vaccines and drugs begins As a rare species of Ebola spreads in DRC and Uganda, Oxford University and the Serum Institute of India (with support from CEPI) have entered an “emergency response arrangement” to develop and manufacture an investigational vaccine ready for te...

05/14/2026

Africa CDC's first African Pooled Procurement Mechanism (APPM) tender for essential medicines for reproductive, maternal and newborn health achieved 30%-90% lower prices compared with member state benchmarks. More on this update and other pharma news important to global health in this week's highlights.

Study: Mosquirix significantly reduced child deaths Introducing Bharat Biotech and GSK’s Mosquirix (RTS,S) malaria vaccine in routine immunization programs in Ghana, Kenya and Malawi averted “about one in eight deaths” among young children over a four-year period. That’s according to study r...

04/30/2026

Last week's World Malaria Day generated a flurry of pharma news important to global health, including WHO's prequalification of Coartem Baby (the Novartis/MMV infant antimalarial), India's sign-off on Phase 3 trials of Zydus Lifesciences' oral antimalarial zintrodiazine, Serum Institute of India's licensing deal with Oxford University for a blood-stage vaccine, and more.

Coartem Baby wins WHO PQ WHO has prequalified Coartem Baby, the newborn-and-infant antimalarial jointly developed by Novartis and Medicines for Malaria Ventures (MMV). Novartis trumpeted the news last week, just ahead of World Malaria Day.

Address

808 Fifth Avenue North
Seattle, WA
98109

Website

http://linksbridge.com/

Alerts

Be the first to know and let us send you an email when Linksbridge posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Linksbridge:

Featured

Trücup coffee roasters

Want your business to be the top-listed Business in Seattle?